Browsing Tag
Vertex Pharmaceuticals
15 posts
Vertex just completed a $10bn acquisition. Why is Jonathan Poole becoming CFO now?
Vertex Pharmaceuticals has split the operating and finance responsibilities held by Charles Wagner as it begins integrating the $10 billion Crinetics Pharmaceuticals acquisition and targets more than $5 billion of potential peak sales from its new endocrine assets.
CRISPR Therapeutics advances one-time cardiovascular strategy as CTX310 lipid reductions persist for a year
CTX310 sustains deep lipid reductions for one year as CRISPR Therapeutics expands its cardiovascular gene-editing strategy. See what comes next.
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps. Read how launch execution, pricing and full approval risks shape the next phase.
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Vertex Pharmaceuticals (Nasdaq: VRTX) gains FDA approval to expand Casgevy to children as young as two
Vertex Pharmaceuticals wins FDA approval to expand Casgevy to children as young as two, reshaping sickle cell treatment economics.
Can povetacicept reshape autoimmune kidney care? Vertex Pharmaceuticals’ RUBY-3 trial shows promise
Vertex’s RUBY-3 trial shows strong 48-week data for povetacicept in IgAN and pMN. Find out how this sets the stage for late-stage trials and regulatory filings.
Non-opioid pain drugs in 2025: Top clinical-stage biotechs to watch
Explore the top biotech companies leading the charge in non-opioid pain relief in 2025, from Allay Therapeutics to Vertex Pharmaceuticals.
The race for non-opioid pain relief: who’s leading the post-opioid era?
Explore the top companies and mechanisms leading the post-opioid pain relief revolution in 2025. Who's winning the race for safe, effective chronic pain drugs?
Sarepta, Palantir, Moderna lead Wall Street declines as biotech, tech stocks tumble
U.S. stock market losers on May 6, 2025: Find out why Sarepta, Palantir, Moderna, Lattice Semiconductor and more saw sharp stock price drops.
Vertex Pharmaceuticals bags UK approval for ALYFTREK, a next-generation cystic fibrosis treatment
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), a next-generation…